Compare · GH vs UNH
GH vs UNH
Side-by-side comparison of Guardant Health Inc. (GH) and UnitedHealth Group Incorporated (UNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GH and UNH operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $336.61B, about 14.2x GH ($23.68B).
- Over the past year, GH is up 186.3% and UNH is up 9.3% - GH leads by 177.0 points.
- UNH has been more active in the news (19 items in the past 4 weeks vs 14 for GH).
- Both have 25 recent analyst ratings on file.
- Company
- Guardant Health Inc.
- UnitedHealth Group Incorporated
- Price
- $177.34+0.53%
- $376.70+0.41%
- Market cap
- $23.68B
- $336.61B
- 1M return
- +3.79%
- -6.06%
- 1Y return
- +186.26%
- +9.25%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 14
- 19
- Recent ratings
- 25
- 25
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest GH
- Director Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 10,274 units (SEC Form 4)
- Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 5% to 5,020 units (SEC Form 4)
- Chief Technology Officer Chudova Darya sold $1,377,364 worth of shares (7,738 units at $178.00), decreasing direct ownership by 10% to 70,635 units (SEC Form 4)
- Director Azar Alex M Ii sold $144,550 worth of shares (826 units at $175.00), decreasing direct ownership by 50% to 825 units (SEC Form 4)
- Director Krognes Steve E. sold $1,172,886 worth of shares (6,674 units at $175.74), decreasing direct ownership by 46% to 7,906 units (SEC Form 4)
- Director Tariq Musa converted options into 249 shares and sold $20,300 worth of shares (116 units at $175.00), increasing direct ownership by 1% to 11,449 units (SEC Form 4)
- SEC Form 144 filed by Guardant Health Inc.
- Director Azar Alex M Ii converted options into 1,651 shares (SEC Form 4)
- Chief Information Officer Kalia Kumud sold $632,193 worth of shares (4,000 units at $158.05), decreasing direct ownership by 9% to 39,794 units (SEC Form 4)
- Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Latest UNH
- Director Mcnabb Frederick William Iii was granted 57 shares, increasing direct ownership by 0.37% to 15,519 units (SEC Form 4)
- Director Noseworthy John H was granted 46 shares, increasing direct ownership by 0.60% to 7,662 units (SEC Form 4)
- Director Baker Charles D. was granted 15 shares, increasing direct ownership by 0.63% to 2,411 units (SEC Form 4)
- Chief Accounting Officer Stankiewicz Dennis Andrew was granted 51 shares, increasing direct ownership by 0.51% to 10,109 units (SEC Form 4)
- Director Flynn Timothy Patrick was granted 68 shares, increasing direct ownership by 0.63% to 10,943 units (SEC Form 4)
- CEO, UHG Hemsley Stephen J was granted 50 shares, increasing direct ownership by 0.03% to 177,690 units (SEC Form 4)
- Director Garcia Paul R was granted 16 shares, increasing direct ownership by 0.41% to 3,922 units (SEC Form 4)
- Director Gottlieb Scott was granted 5 shares, increasing direct ownership by 0.76% to 664 units (SEC Form 4)
- Director Montgomery Rice Valerie Md was granted 47 shares, increasing direct ownership by 0.60% to 7,923 units (SEC Form 4)
- EVP & Chief Legal Officer Zaetta Christopher R was granted 67 shares, increasing direct ownership by 0.42% to 15,927 units (SEC Form 4)